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Abstract
Background: Cutaneous Leishmania major has affected many travelers including military personnel in Iraq and Afghanistan.
Optimal treatment for this localized infection has not been defined, but interestingly the parasite is thermosensitive.
Methodology/Principal Findings: Participants with parasitologically confirmed L. major infection were randomized to
receive intravenous sodium stibogluconate (SSG) 20mg/kg/day for ten doses or localized ThermoMed (TM) device heat
treatment (applied at 50uC for 30 seconds) in one session. Those with facial lesions, infection with other species of
Leishmania, or more than 20 lesions were excluded. Primary outcome was complete re-epithelialization or visual healing at
two months without relapse over 12 months. Fifty-four/56 enrolled participants received intervention, 27 SSG and 27 TM. In
an intent to treat analysis the per subject efficacy at two months with 12 months follow-up was 54% SSG and 48% TM
(p=0.78), and the per lesion efficacy was 59% SSG and 73% TM (p=0.053). Reversible abdominal pain/pancreatitis,
arthralgias, myalgias, headache, fatigue, mild cytopenias, and elevated transaminases were more commonly present in the
SSG treated participants, whereas blistering, oozing, and erythema were more common in the TM arm.
Conclusions/Significance: Skin lesions due to L. major treated with heat delivered by the ThermoMed device healed at a
similar rate and with less associated systemic toxicity than lesions treated with intravenous SSG.
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Introduction
Cutaneous leishmaniasis is a parasitic infection transmitted by
the bite of an infected sand fly, with an estimated worldwide
incidence of 1.5 million cases [1]. Generally self resolving within
months, infection with Leishmania major can leave disfiguring scars
or chronic ulcers, usually in areas not covered with clothing. Since
2003, the U.S. military has reported .1,300 cases of cutaneous
leishmaniasis in Army soldiers [2]. While systemic use of the
pentavalent antimonial sodium stibogluconate (Pentostam, Glaxo
Smith Kline, United Kingdom) showed efficacy with treatment
responses .90% in cutaneous leishmaniasis, field ready treatment
of short duration using limited supplies or equipment was
considered preferable [3].
Dermatotrophic Leishmania species such as L. major, L. tropica,
and L. mexicana are thermosensitive with higher temperatures
limiting amastigote replication [4–6]. In mice infected with L.
mexicana, environmental therapy at 37uC for 4–6 weeks was
compared to ten day cycles of intralesional meglumine anti-
moniate. Thermotherapy was associated with more rapid
resolution compared to antimonial treatment but both had similar
cure rates at 10 weeks (93% and 88% respectively). All untreated
control animals had large lesions by week 19 [7].
Heat treatment of leishmaniasis has been delivered by various
methods, including hot water soaks, circulating hot water in
heating pads, alternating ultraviolet and infrared heat, and
ultrasonically induced hyperthermia of the skin [8–11]. Clinical
trials used several devices which provided localized current from
www.plosntds.org 1 March 2010 | Volume 4 | Issue 3 | e628radiofrequency instruments to generate heat in affected tissue
[12–19]. One of these instruments, ThermoMed Model 1.8,
(Thermosurgery Technologies, Inc., Phoenix, AZ) has received
510(K) clearance from the Food and Drug Administration (FDA)
for treatment of cutaneous leishmaniasis. Published experience
suggests thermotherapy efficacy was similar to or better than
intralesional or parenteral pentavalent antimonial treatment, but
the studies used differing entry criteria, parasite species, follow-up,
and outcome definitions [12,15–19]. Our controlled trial provides
detailed information about the course and toxicity in well
characterized cases of dermatotrophic L. major in ‘‘traveling’’
soldiers without prior immunity. Our subjects left the endemic
region by the time of treatment and were adherent with follow-up,
thereby eliminating factors that plagued prior studies.
Methods
Participants/Study Location
The trial was performed at Walter Reed Army Medical Center
(WRAMC) in Washington, DC in 2004–6. Eligible participants
were Department of Defense health care beneficiaries with
parasitologically confirmed cutaneous leishmaniasis. Based on
travel history, all participants were likely infected in Iraq or
Kuwait. All were treatment naive. Randomization criteria
included L. major species confirmation. Exclusionary criteria were
.20 lesions, pregnancy, lactation, hypersensitivity to pentavalent
antimonials or local anesthetics, serious medical illness, lesion in
proximity to mucous membranes, face, or cartilage, implanted
metallic devices, or unwillingness to avoid procreation for at least
two months. The protocol received Institutional Review Board
approval at Walter Reed Army Medical Center and all
participants provided written informed consent. A sample size of
27 participants per treatment group was planned, assuming a 73%
Author Summary
Cutaneous leishmaniasis, a parasitic skin infection trans-
mitted by the bite of a sand fly, can result in chronic skin
sores and is estimated to affect more than 1.5 million
persons worldwide. While the infection generally heals on
its own in months to years, treatment can be expensive
and difficult. We compared a heat treatment using the
ThermoMed device to an (abbreviated) ten day course of
intravenous Pentostam (a pentavalent antimony drug) in a
population of U.S. soldiers who acquired their infections in
Iraq. We found no statistically significant difference
between the two treatments in the healing rate at two
months. The heat treatment had less associated toxicity.
Heat therapy is a ruggedized, battery operated method
that could be adapted to humanitarian situations and less
developed health care settings, likely with less cost and
side effects than local treatment alternatives.
Figure 1. Study flow diagram.
doi:10.1371/journal.pntd.0000628.g001
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probability of a Type I error at alpha =0.05 and was predicted to
have 80% power to determine a 26% difference in outcome.
Study Interventions
This controlled trial compared 10 days of 20 mg/kg/day
intravenous sodium stibogluconate (SSG, GlaxoSmithKline,
United Kingdom) to one treatment session using the ThermoMed
Model 1.8 device (TM). SSG was infused over 10–50 minutes for a
total of 10 doses. Participants randomized to thermotherapy
received oral antibiotics for secondary bacterial infections of the
leishmaniasis lesion(s) prior to treatment (SSG arm participants
were treated concurrently). Prior to thermotherapy, each lesion
was cleansed, anesthetized, moistened, and overlying eschar was
removed. Two trained physicians performed TM treatments. The
TM probe was placed on the skin, covering the lesion with 50uC
TM treatments applied for 30 seconds in a grid fashion extending
4mm into border skin. The lesion size determined the number of
applications. Each lesion was then covered with a dressing
(Coverlet, Beiersdorf-Jobst, Wilton CT) that was changed daily.
Participants were seen daily for 10 days with physical examination,
laboratory testing (complete blood count, creatine phosphokinase,
amylase, lipase, complete metabolic profile), and electrocardio-
grams at baseline, days 3, 7, 10. Interview follow-up by telephone,
email, letter, or infrequently in person, occurred at 2, 6, and 12–24
months post treatment. Photographs were taken at baseline, day
10, and requested with 2, 12 month follow-ups. Sequential
photographs were independently assessed by blinded leishmaniasis
experts, who were clinicians experienced in the treatment of CL,
with a tiebreaker assessment when needed. Participants with
clinical failure at 2 months were offered crossover treatment.
Objectives
The primary study objective was to compare efficacy of local
thermotherapy with the TM device to a 10 day course of
parenteral SSG, (IND# 14150), to treat cutaneous L. major (2
months post treatment). Secondary objectives included compari-
son of the treatment toxicity profiles.
Study Outcome Measures
Clinical cure was defined as complete epithelialization or visually
healed at 261 month after completion of therapy and no reactivation
in 12 months after the start of treatment. Clinical failurewas less than
complete epithelialization or visually not healed at 261m o n t ha f t e r
treatment completion. Relapse failure was defined as skin lesion
persistence at the treatment site or elsewhere in the period up to 12
months after start of therapy, regardless of appearance at 261m o n t h
after treatment completion. The overall treatment responses are
reported as determined by: subject, blinded expert photograph
review, and consensus response where photograph review was the
prioritized outcome but subject assessment was used when
photographs were not provided or were inadequate for review.
Randomization
The statistician (RH) generated the randomization plan in
blocks of 4 subjects using www.randomization.com. The research
pharmacist made assignments using the randomization plan in
sequential order. The allocation sequence was unavailable to
investigators until completion of the trial.
Parasitologic Confirmation
Diagnosis was confirmed prior to enrollment using skin scrapings
or biopsy from one characteristic lesion per subject. Histology was
reviewed at the Armed Forces Institute of Pathology, Washington,
DC. Leishmania culture and genus/species PCR were done at the
Walter Reed Army Institute of Research, Silver Spring, MD.
Speciation was determined by isoenzyme analysis of positive
cultures and a glucose phosphate isomerase (GPI) based RT-PCR
assay for Leishmania genus PCR positive samples [21].
Statistical Methods
Subject data were entered into Access (Microsoft) software and
analyzed in SPSS (Windows v17, SPSS Inc., Chicago, IL). Groups
were compared using Fisher’s exact test and the Wilcoxon rank
sum test. Logistic regression and the Mantel Haenszel test were
used to examine the effect of multiple risk factors on healing. Serial
laboratory assessments were compared using repeated measures
analysis of variance. Data not satisfying assumptions of normality
were logarithmically transformed. All p values are two-sided and
p,0.05 was considered statistically significant. Study data were
analyzed in an intent to treat (ITT) basis with missing data
handled as missing. The four treatment crossover subjects were
considered failed in the analysis, the twelve month outcome was
not evaluable given multiple treatment modalities.
Results
We enrolled 56 participants but two were subsequently excluded:
one lacked confirmed speciation and one for olecranon bursitis
under a lesion which might have been associated with excessive
Table 1. Baseline Demographic Characteristics Compared by
Treatment.
TM SSG p value
Characteristic per patient n=28 n=28
Median age in years (range) 25 (20–53) 24 (18–57) 0.16
Male gender (%) 28 (100) 27 (96) 0.99
Race
Caucasian (%) 15 (54) 18 (64) 0.84
African American (%) 7 (25) 5 (18)
Hispanic (%) 4 (14) 4 (14)
Other (%) 2 (7) 1 (4)
Median number of lesions (range) 2 (1–14) 3 (1–17) 0.74
Median duration lesion in days, (range) 126 (45–231) 138 (50–270) 0.75
Amastigotes present (%) 22 (79) 18 (64) 0.38
Culture isoenzyme L. major* (%) 12/23 (52) 12/24 (50) 0.99
L. major species PCR positive 28 (100) 27 (96) 0.99
Complicated leishmaniasis** (%) 5 (18) 8 (29) 0.53
Characteristic per lesion n=94 n=97
Median size of lesion mm
2 (range)*** 155 (9–1014) 110 (9–1720) 0.14
Location of lesion (%) 0.002
Head & Neck 11 (12) 6 (6)
Arms 40 (43) 65 (67)
Legs 27 (29) 14 (14)
Back 11 (12) 3 (3)
Chest 5 (5) 9 (9)
*Not all subjects had parasite culture done so denominator given in table.
**Presence of significant regional adenopathy or subcutaneous nodules.
***Size is length x width of skin lesion.
doi:10.1371/journal.pntd.0000628.t001
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prescribed treatment. Figure 1 shows good adherence with study
follow-up visits. End points and follow-up data were available for all
but one SSG treated participant who withdrew from follow-up after
the 6 month visit. Participantsreceivingcrossover treatment and the
withdrawn subject were unable to be assessed for the 12 month
outcome (3 in TM, 2 in SSG), although all eligible were contacted
(n=4) and endorsed being healed.
The baseline demographic characteristics (Table 1) were
similar between treatment arms with the exception of lesion
location. In the SSG treatment group there was a higher number
of arm and chest lesions and fewer neck, leg, and back lesions. All
treated participants had parasitologic confirmation of L. major
infection.
In an ITT analysis at two months after the completion of
treatment, 12/25 evaluable TM participants (48%) and 14/26
SSG treated participants (54%) were assessed as clinically cured
with complete and durable healing of all lesions (p=0.78, odds
ratio: 0.79, (95% CI: 0.26–2.38)). At 2 months, 63 TM treated
lesions (73%) versus 50 SSG treated lesions (59%) were assessed
as clinically cured (p=0.053, odds ratio: 1.92 (95% CI: 1.01–
3.65)). There were two relapse failures. Relapses occurred prior
to the six month follow-up and in the TM arm included
activation/ulceration at a site not treated, subcutaneous nodules
forming around the treated area, or breakdown within the edge
of the TM treated area. After the two month follow-up, three
persons in the TM assigned arm crossed over to SSG and one
person in the SSG assigned arm was subsequently retreated with
TM. Other participants with clinical failure at 2 months elected
for no further treatment. The survival analysis of time to healing
for the two treatment arms (Figure 2) suggested that participants
in the SSG treated arm appreciated a more rapid time to
healing as compared to thermotherapy treated (p=0.058) when
healing was based solely on patient evaluation. This difference
was not found in the analysis using blinded reading of
photographs where the efficacy by treatment was statistically
similar (p=0.24).
The demographics of participants with clinical cure at 2 months
versus failure (Table 2) suggested no difference in race, duration of
lesion, lesion size, or number of TM treatments/lesion. Subjects
with clinical cure were 3 years younger (p=0.019). There was a
difference in the participant response between the two TM
operators (p=0.019), but not a per lesion response difference,
(p=0.38). The operator with the higher failure rate treated
subjects with more lesions (median=3, range: 1 to 14) compared
to a median of 2 (range: 1 to 4) for the other operator (p=0.06).
Among those participants with clinical failure, the median number
of lesions was higher (p=0.026) and lesion location also differed
with more arm, chest involvement in those failing (p=0.001).
When the number of lesions and age were included in a
multivariate analysis, the difference between treatment groups
was not significant (p=0.85, odds ratio: 0.89 (95% CI: 0.27–2.91)).
When location was taken into account in the analysis of lesions,
treatment groups did not differ significantly (p=0.30, odds ratio:
1.44 (95% CI: 0.72–2.86)). Complete cure at two months after
completion of treatment was a very stringent outcome assessment,
so we compared clinical outcome where participants were graded
as ,50% lesions healed, $50% lesions healed and 100% lesions
healed. This demonstrated no significant differences in efficacy
between treatment arms at the 2 or 12 month follow-ups (Figure 3).
A secondary objective was comparison of toxicity profiles. Daily
physician evaluations occurred during treatment with frequent
laboratory and electrocardiogram evaluation. There were seven
serious adverse events, four in the TM arm and three in the SSG
Figure 2. Time to healing by patient self report or by photographs.
doi:10.1371/journal.pntd.0000628.g002
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treatment, consisting of a basal cell carcinoma diagnosis prior to
treatment and hospitalizations during the follow-up period for
gastroenteritis, elective repair of the left acromioclavicular joint,
pneumonia, surgery for rectal carcinoid, inflammatory bowel
disease, and trauma from a motor vehicle accident. Serial
laboratory values over the 10 day treatment, segregated by
treatment modality, show statistically significant decreases in white
blood cells, hematocrit, platelets, and increases in amylase, lipase,
ALT, AST in those receiving SSG (Table 3). Of note, changes in
creatinine, corrected QT interval, and creatine kinase (CK) were
similar.
After treatment initiation, there were five lesion-related wound
infections (19%) in the TM treated arm and one (4%) in the SSG
treated group (p=0.19). In the TM arm, the median time to
wound infection after treatment was 10 days (range 3–75). Lesion
reactions associated with TM included blister 25 (93%), oozing 21
(78%), and keloid 2 (7%). Participant description of their lesions
showed no qualitative difference between treatment arms at the
12–24 months follow-up. Chest pain, abdominal discomfort,
diarrhea, nausea, vomiting, arthralgias/myalgias, rash, headache,
dizziness, fatigue, and pyrexia were more common in the SSG
treated arm, (Table 4). Among SSG treated participants, 82%
developed elevated amylase or lipase at some time versus none in
the TM treated arm. 46% SSG and 7% TM treated developed
elevated ALT/AST. CK was increased over baseline values in
25% SSG and 32% TM.
Discussion
Standard treatment practice in the U.S. for cutaneous L. major
includes no treatment (generally for ,5 uncomplicated skin
lesions), use of investigational drugs including SSG, miltefosine,
paromomycin, or off label use of azoles or amphotericin products.
These present an array of adverse effects to consider in each
individual with a cosmetically concerning/scarring dermal infec-
tion generally not associated with systemic complications.
Table 2. Characteristics of those healed versus failed at two
months.
Clinical
Cure
Clinical
Failure p Value
Characteristic per patient n=26 n=25
Median age in years (range) 23 (19–38) 26 (18–57) 0.019
Race 0.99
Caucasian (%) 15 (58) 16 (64)
African American (%) 6 (23) 5 (20)
Hispanic (%) 3 (11) 3 (12)
Other (%) 2 (8) 1 (4)
Median # lesions (range) 2 (1–14) 3 (1–17) 0.026
Median duration lesion in days (range) 115 (45–270) 138 (55–196) 0.82
ThermoMed operator/patient 0.015
Dr. X (n=15) 4 (33) 11 (85)
Dr. Z (n=10) 8 (67) 2 (15)
Characteristic per lesion n=113 n=63
Median size of lesion in mm
2 (range) 130 (9–1720) 135 (12–750) 0.62
Location of lesion 0.001
Head & Neck (%) 9 (8) 6 (10)
Arms (%) 53 (47) 40 (69)
Legs (%) 34 (30) 3 (5)
Back (%) 10 (9) 3 (5)
Chest (%) 7 (6) 6 (10)
ThermoMed treated lesions only
ThermoMed operator/lesion 0.38
Dr. X (n=69) 48 (76) 20 (87)
Dr. Z (n=19) 15 (24) 3 (13)
Median no. of ThermoMed Tx/lesion 2 (0–13) 3 (1–7) 0.076
doi:10.1371/journal.pntd.0000628.t002
Figure 3. Consensus treatment efficacy at two and twelve months follow-up.
doi:10.1371/journal.pntd.0000628.g003
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TM was as effective as 10 days of intravenous SSG at 20mg/kg/
day in L. major infection in American soldiers. Our primary
endpoint of healing at two months with no reactivation over 12
months showed 48% TM and 54% of SSG treated participants
achieved a clinical cure. Additionally, per lesion analysis showed
73% of TM treated lesions and 59% of SSG treated lesions at 2
months follow-up were clinical cures (p=0.053). We had
excellent adherence; all receiving study treatment completed
the course with daily physician follow-up for ten days.
Unexpectedly, interview responses from participants regarding
outcome at 2, 6, 12–24 months suggested a perception that SSG
was associated with more rapid healing (p=0.058). This was not
corroborated by the expert (blinded) committee assessment of
lesion photographs. We speculate a perception bias developed
among participants that TM was a less potent treatment (SSG is a
standard treatment at WRAMC and does not initially enlarge the
lesion like TM). Participants generally endorsed no perceived
cosmetic outcome difference between the treatments at the latest
follow-up.
We monitored toxicity of TM and SSG with laboratory and
electrocardiogram testing, daily physician assessments for 10 days
after treatment and long follow-up (12–24 months). The
thermotherapy arm provided insight into the differential frequency
of adverse effects of a 10 day course of intravenous pentavalent
antimony. Systemic effects including pancreatitis (67%), arthral-
gias, myalgias (59%), headache (44%) and fatigue (67%) were
more likely in the SSG treated group and local effects of lesion
blistering (93%), oozing (78%), and erythema (26%) were more
likely in the TM (which causes a burn) treated arm. Interestingly,
there was no statistical difference in electrocardiogram findings,
including changes in QTc, between the two treatment groups.
Compared to the typical SSG regimen of 20 days in a similar
military population, the magnitude of change in laboratory values
was lower in the 10 day SSG infusion course [3].
Previous studies of thermotherapy in Old World cutaneous
leishmaniasis have suggested reasonable but variable efficacy. A
small observational study in U.S. soldiers showed 88% efficacy of
TM treatment with a 6 months follow-up [16]. A large
randomized trial in Afghanistan of presumed L. tropica using the
Table 3. Median laboratory values over time, compared by treatment group.
Median Value (range) Baseline Day 3 Day 7 Day 10 p value*
WBC in TH/CUMM 0.017
TM 7.2 (4.0,12.5) 6.8 (3.6, 11.2) 7.0 (3.8, 12.2) 6.4 (3.9, 10.3)
SSG 7.9 (3.5, 12.4) 5.9 (3.0, 9.0) 5.5 (2.9, 12.0) 4.9 (3.1, 10.6)
Hematocrit % ,0.001
TM 44.6 (36.8, 56.6) 45.4 (36.9, 53.5) 44.8 (38.3, 52.6) 45.9 (40.9, 50.9)
SSG 44.3 (35.4, 55.3) 44.1 (37.7, 51.5) 44.0 (38.1, 51.0) 43.1 (37.6, 47.7)
Platelets TH/CUMM ,0.0005
TM 250 (171, 353) 233 (170, 323) 237 (167, 302) 236 (181, 291)
SSG 250 (179, 333) 229 (180, 310) 206 (134, 289) 196 (133, 294)
Amylase U/L ,0.0005
TM 51 (,30, 101) 48 (30, 104) 52 (30, 93) 52 (33, 88)
SSG 50 (,30, 107) 127 (34, 420) 152 (,30, 511) 143 (,30, 348)
Lipase U/L ,0.0005
TM 72 (29, 254) 61 (29, 224) 75 (28, 212) 70 (19, 253)
SSG 76 (26, 204) 512 (95, 2479) 587 (103, 6009) 515 (97, 2385)
Creatinine mg/dL 0.92
TM 1.0 (0.8, 1.2) 1.0 (0.9, 1.2) 1.0 (0.8, 1.2) 1.0 (0.8, 1.2)
SSG 1.0 (0.7, 1.3) 1.0 (0.8, 1.3) 0.9 (0.7, 1.4) 0.9 (0.7, 1.3)
CK U/L 0.91
TM 103 (60, 17763) 102 (57,1475) 117 (54, 522) 110 (57, 572)
SSG 78 (52, 220) 97 (39, 453) 90 (34, 206) 78 (34, 404)
ALT U/L ,0.0005
TM 30 (22, 86) 29 (19, 86) 32 (17, 73) 30 (21, 77)
SSG 27 (16, 61) 27 (14, 67) 46 (22, 400) 71 (28, 305)
AST U/L ,0.0005
TM 22 (18, 187) 25 (17, 70) 25 (17, 35) 27 (16, 55)
SSG 23 (13, 42) 23 (14, 52) 37 (18, 285) 52 (26, 135)
QTc ms 0.24
TM 403 (369, 437) 403 (319, 440) 401 (378, 457) 402 (372, 457)
SSG 399 (377,450) 402 (377, 438) 403 (368, 447) 403 (376, 438)
*p Values represent interaction of treatment and time (e.g. a significant p value indicates that the effect of the treatment over time was significantly different).
doi:10.1371/journal.pntd.0000628.t003
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lesser efficacy (45%) with intramuscular SSG (Albert Davis Ltd,
India) with a maximum dose of 850 mg per day [17]. In Iran
(presumed L. major species) a different radiofrequency heating
device was used in four weekly sessions compared to intralesional
meglumine antimoniate with 6 month efficacy of 81% for
thermotherapy and 55% for intralesional antimonial [18]. Studies
of thermotherapy in New World cutaneous leishmaniasis have also
suggested efficacy: 73% in Guatemala [12], 90% at eight weeks in
Mexico [14], 71% in Brazil at 28 days [15], and 100% per
protocol but 19% in ITT analysis in Colombia at 100 days [19].
Our study has an early outcome measure at 2 months after the
start of treatment, although information at 6 months was also
obtained. It is difficult to identify another OWCL study where
similar species (often mixed/not specified L tropica and L. major) and
outcome definition were applied at 2 months. We tested a shorter
course using full dose intravenous SSG (no upper limit to the daily
weight based dose) which has not been studied head to head in a
randomized trial of other agents. While the standard duration of
intravenous SSG is 20 days, a previous study at our center
suggested similar efficacy using a 10 day course at 6 month follow-
up, with less toxicity [21]. From 2003–6, in 141 L. major patients
treated at our center we found 92% clinical cure with SSG 10
versus 95% in SSG 20 patients (n=273) at six months follow-up
[personal communication Aronson]. Importantly, this thermo-
therapy study findings suggest that a single heat treatment of
cutaneous leishmaniasis with a FDA ‘approved’ device suitable for
resource limited areas has similar healing rates to SSG for 10 days.
We further described the efficacy and lower toxicity seen with
short duration intravenous SSG therapy in L. major infection.
The strengths of our study include a randomization, similar
detailed assessments of both treatment arms, prolonged follow-up,
excellent adherence, parasitologic species confirmation, and
rigorous outcome assessment with treatment blinded experts
reviewing lesion photographs supplemented with participant’s
impression. A universal measure of healing in Old World
cutaneous leishmaniasis is lacking but the standard timepoint
seems to be 3 months after treatment [22]. We chose an earlier
timepoint to maximize our observation of the effect of our
interventions in a self healing infection. Regarding study
limitations, our study lacks a placebo arm to address the self
healing observed with time and variably described as 10–68% in a
systematic review in L. major [23]. A Cochrane review suggested L.
major self heals in 2–3 months, but may persist up to 5 years [22].
In our study, the median duration of skin lesions prior to treatment
exceeded 120 days; there likely was a referral bias for more
persistent and severe L. major infection being sent back to the U.S.
for treatment. Regarding diagnosis, only one lesion was sampled
per participant and unresponsive skin lesions may not always have
been cutaneous leishmaniasis, however in a randomized clinical
trial this is unlikely to have a differential effect. The generaliz-
ability of our results is limited to L. major lesions excluding the face,
of moderate size (mean 205 mm
2), in otherwise healthy men who
constituted our study population. The outcome assessment was
restricted by the lower quality of some and incomplete provision of
returned photographs as well as subjective information relayed by
the participants rather than in person evaluations during the
follow up.
The clinical implications of our study are that a single
thermotherapy treatment showed similar healing rates and was
as well tolerated as a 10 day infusion of SSG for L. major infection.
Thermotherapy devices are portable, multi-use, and easy to
operate in resource limited environment. This contrasts to the
time, labor, and cost involved using an intravenous investigational
new drug such as SSG under FDA regulations which required
transfer to the U.S. for our subjects. Recognizing that L. major
often results in a self healing infection, the choice of treatment
intervention should weigh patient wishes, and consider the
number, location, duration, size of lesions, and signs of local
dissemination. Thermotherapy is generally well tolerated and may
limit the size of subsequent scar. The effect is local so use in
disseminated infection is not recommended. Large numbers of
lesions and very large lesions require a significant amount of time
to treat with the device. To mitigate the risk of secondary wound
infection of the burn, others have used topical bacterial ointment
during the initial post treatment period [16]. Analyses have not
found antimonial treatment of cutaneous leishmaniasis as cost-
effective. While thermotherapy cost has not been included in these
models, it is likely to be cost-effective in endemic areas [17,24,25].
Future research could assess whether thermotherapy treated areas
Table 4. Common adverse events compared by treatment
arm*.
Adverse Event TM SSG p value
(n=27) (n=27)
Cardiac Disorders n (%) 10 (37) 15 (56) 0.28
EKG changes 10 (37) 14 (52) 0.41
Chest pain 0 (0) 3 (11) 0.24
Palpitations 0 (0) 1 (4) 0.99
Gastrointestinal n (%) 3 (11) 18 (67) ,0.0005
Abdominal discomfort/pain 1 (4) 12 (44) 0.001
Diarrhea 2 (7) 7 (26) 0.14
Nausea 2 (7) 8 (30) 0.076
Vomiting 0 3 (11) 0.24
Infection n (%) 9 (33) 6 (22) 0.54
Wound infection 5 (19) 1 (4) 0.19
Leishmania lesion reaction n (%)
Blister 25 (93) 0 (0) ,0.0005
Erythema 7 (26) 1(4) 0.05
Keloid 2 (7) 0 (0) 0.49
Oozing 21 (78) 2 (7) ,0.0005
Musculoskeletal n (%) 5 (19) 18 (67) 0.0010
Arthralgias 3 (11) 16 (59) ,0.0005
Myalgias 2 (7) 12 (44) 0.004
Nervous system n (%) 5 (19) 17 (63) 0.002
Headache 3 (11) 12 (44) 0.014
Dizziness 2 (7) 4 (15) 0.67
Respiratory n (%) 3 (11) 6 (22) 0.47
Cough 0 (0) 2 (7) 0.49
Dyspnea 1 (4) 1 (4) 0.99
General n (%) 5 (19) 23 (85) ,0.0005
Fatigue 5 (19) 18 (67) 0.001
Pyrexia 0 (0) 4 (15) 0.11
Skin n (%)
Rash 1 (4) 4 (15) 0.35
Serious adverse events n (%) 4 (15) 3 (11) 0.99
(All are no or remote relationship).
*Each event counted once per participant.
doi:10.1371/journal.pntd.0000628.t004
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healing post SSG; if not, then the implication of lessened risk of
later reactivation but also the role of potentially lessened
protection from reinfection might be better understood [26,27].
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